Judy Li, PhD

AstraZeneca

Dr. Judy Li, PhD, is the Head of Hematology Strategy Late Oncology Statistics at AstraZeneca, where she provides leadership and expertise in oncology statistics, with a keen focus on strategic planning, technical oversight, functional development, and operational guidance. Throughout her career, Dr. Li has held senior leadership positions in both the biopharmaceutical and biotech sectors, making significant contributions at organizations including Bristol Myers Squibb, Celgene, and Regeneron Pharmaceuticals. Prior to her industry tenure, she garnered extensive experience at the US Food and Drug Administration as a master statistical reviewer and supervisory mathematical statistician. Her clinical development experience across multiple therapeutic areas including oncology, hematology, immunology, neurology, cell therapy, as well as special clinical settings for multiregional clinical trials and rare disease.

As an active member of the American Statistical Association (ASA) Biopharmaceutical Section Executive Board for more than a decade, Dr. Li has taken on multiple responsibilities and roles within the board. She is currently Biopharmaceutical Section chair-elect for 2026, was the co-founder of the Safety Monitor Scientific Working Group, the chair of 2019 Regulatory Industry Statistics Workshop, the chair of poster competition section and membership committee.

Dr. Li received her PhD in Statistics from the University of California, Riverside and her MBA degree majored in Strategic Management from the Wharton Business School University of Pennsylvania. She is the editor of book Quantitative Methodologies and Process for Safety Monitoring and Ongoing Benefit Risk Evaluation. Her research work has been highly acknowledged with the FDA Office of Chief Scientist and received the Intramural Grant award for two consecutive years.